Drug interactions
Docetaxel + Rucaparib
Severity: Minor
Docetaxel and Rucaparib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Rucaparib is a weak inhibitor of CYP3A4 and may modestly raise exposure to docetaxel, a CYP3A4 substrate with a narrow therapeutic index. Increased docetaxel exposure could worsen neutropenia, neuropathy and fluid retention. The clinical effect is expected to be small.
What this interaction means in plain words
Docetaxel and Rucaparib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Docetaxel belongs to Oncology; Rucaparib belongs to Oncology.
Why it happens
Rucaparib weakly inhibits CYP3A4, reducing docetaxel metabolism.
What to do
Monitor blood counts and docetaxel toxicity during combined therapy. Reduce the docetaxel dose only if toxicity emerges.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Docetaxel and Rucaparib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Docetaxel
Other interactions of Rucaparib
- Cisapride + Rucaparib Major
- Ergotamine + Rucaparib Major
- Pimozide + Rucaparib Major
- Alfuzosin + Rucaparib Moderate
- Aripiprazole + Rucaparib Moderate
- Atorvastatin + Rucaparib Moderate
Frequently asked questions
Can I take Docetaxel with Rucaparib?
MediHelp rates the interaction as minor. Docetaxel and Rucaparib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Rucaparib is a weak inhibitor of CYP3A4 and may modestly raise exposure to docetaxel, a CYP3A4 substrate with a narrow therapeutic index. Increased docetaxel exposure could worsen neutropenia, neuropathy and fluid retention. The clinical effect is expected to be small.
How serious is the interaction between Docetaxel and Rucaparib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and docetaxel toxicity during combined therapy. Reduce the docetaxel dose only if toxicity emerges.
What other medicines interact with Docetaxel?
MediHelp also lists interactions of Docetaxel with, for example, Adenovirus types 4 and 7 live, Atazanavir, Belatacept. The full list is on the Docetaxel page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
